Literature DB >> 214228

Synergistic effect of tumor virus transformation and tumor promoter treatment on the production of plasminogen activator by chick embryo fibroblasts.

R H Goldfarb, J P Quigley.   

Abstract

Cultures of Rous sarcoma virus-transformed chick embryo fibroblasts (RSVCEF) produce 50-fold more of the protease plasminogen activator (PA), than do normal chick embryo fibroblasts. Treatment of RSVCEF cultures with the tumor promoter phorbol myristate acetate (PMA) further enhances (8- to 12-fold) the level of PA activity. Increased levels of PA activity in RSVCEF are observed as early as 1 to 2 hr after PMA treatment. Sodium dodecyl sulfate-polyacrylamide gel electrophoresis demonstrates that the PA produced by PMA-treated cultures has a molecular weight identical to that of the PA produced by untreated cultures. PA induction by PMA cannot be accomplished in cell-free extracts, but requires protein synthesis in intact cells. Under serum-free conditions, PMA-treated RSVCEF secrete high levels of PA for 4 to 6 days and undergo pronounced morphological alterations. Modified culture conditions and the use of PMA to induce PA has allowed for the accumulation of large amounts of RSVCEF culture fluid and the subsequent purification of the enzyme. The sensitivity of transformed CEF to PMA and the generation of enhanced proteolytic activity in the cellular microenvironment may provide a model system to examine the role of both PA in malignant transformation and PMA in tumor promotion.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 214228

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  12 in total

Review 1.  Tumor invasion and host extracellular matrix.

Authors:  B U Pauli; D E Schwartz; E J Thonar; K E Kuettner
Journal:  Cancer Metastasis Rev       Date:  1983       Impact factor: 9.264

2.  Further studies on the mitogenic and immune-modulating effects of plasminogen activator.

Authors:  M A Wainberg; E Israel; R G Margolese
Journal:  Immunology       Date:  1982-04       Impact factor: 7.397

Review 3.  The role of urokinase-type plasminogen activator in aggressive tumor cell behavior.

Authors:  J E Testa; J P Quigley
Journal:  Cancer Metastasis Rev       Date:  1990-12       Impact factor: 9.264

4.  A novel leupeptin-sensitive serine endopeptidase present in normal and malignant rat mammary tissues.

Authors:  I Eto; M D Bandy
Journal:  Mol Cell Biochem       Date:  1990-04-18       Impact factor: 3.396

5.  Differential modulation of plasminogen activator gene expression by oncogene-encoded protein tyrosine kinases.

Authors:  S M Bell; D C Connolly; N J Maihle; J L Degen
Journal:  Mol Cell Biol       Date:  1993-09       Impact factor: 4.272

6.  12-O-tetradecanoylphorbol 13-acetate-inducible proteins are synthesized at an increased rate in Bloom syndrome fibroblasts.

Authors:  U Mallick; H J Rahmsdorf; N Yamamoto; H Ponta; R D Wegner; P Herrlich
Journal:  Proc Natl Acad Sci U S A       Date:  1982-12       Impact factor: 11.205

7.  Differentiation-linked secretion of urokinase and tissue plasminogen activator by normal human hemopoietic cells.

Authors:  E L Wilson; G E Francis
Journal:  J Exp Med       Date:  1987-06-01       Impact factor: 14.307

8.  Production of plasminogen activators by human T-cell leukaemia virus-transformed human T cell lines.

Authors:  S Hinuma; S Honda; K Tsukamoto; K Sugamura; Y Hinuma
Journal:  Br J Cancer       Date:  1985-06       Impact factor: 7.640

9.  Phorbol ester and mitogens stimulate human fibroblast secretions of plasmin-activatable plasminogen activator and protease nexin, an antiactivator/antiplasmin.

Authors:  D L Eaton; J B Baker
Journal:  J Cell Biol       Date:  1983-08       Impact factor: 10.539

10.  Production of plasminogen activator by human natural killer cells. Large granular lymphocytes.

Authors:  R H Goldfarb; T Timonen; R B Herberman
Journal:  J Exp Med       Date:  1984-03-01       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.